Top entities: ADMA Biologics, Kahn Swick & Foti, Charles Foti, Lewis Kahn, United States — United States District Court for the District of New Jersey.

What category does this event fall under?

Regulatory — classified as securities class action.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 10, 2026. Coverage continues to evolve.

Regulatory securities class action

ADMA Biologics class action lawsuit

Q: When did this event occur?

First reported Jul 06, 2026; last updated Jul 10, 2026.

Q: What is the market impact?

General. The lawsuit may negatively impact ADMA's stock price due to allegations of fraud and potential financial penalties.

Analysis based on 6 articles · First reported Jul 06, 2026 · Last updated Jul 10, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The lawsuit may negatively impact ADMA's stock price due to allegations of fraud and potential financial penalties. Investor confidence could be shaken, leading to increased volatility and possible settlement costs.

Biotechnology Pharmaceuticals

Event Summary

Kahn Swick & Foti, LLC (KSF) has filed a class action securities lawsuit against ADMA Biologics, Inc. on behalf of investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The lawsuit, pending in the United States — United States District Court for the District of New Jersey, alleges that ADMA and certain executives failed to disclose material information in offering documents, including an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Investors have until August 10, 2026 to seek lead plaintiff status.

Key Actions

90 Kahn Swick & Foti notified investors of lawsuit ADMA Biologics

Entities Involved

stock

ADMA Biologics

ADMA Biologics is the defendant in the class action lawsuit, facing allegations of securities fraud that could result in financial damages and reputational harm.

Importance 100.0 Sentiment -60.0

priv

Kahn Swick & Foti

Kahn Swick & Foti is the law firm representing the plaintiff class, seeking to recover losses for investors.

Importance 80.0 Sentiment 10.0

per

Charles Foti

Charles C. Foti, Jr. is a partner at KSF and former Louisiana Attorney General, lending his name to the case.

Importance 30.0 Sentiment 0.0

per

Lewis Kahn

Lewis Kahn is the managing partner at KSF and the primary contact for investors seeking information about the lawsuit.

Importance 20.0 Sentiment 0.0

govactor

United States — United States District Court for the District of New Jersey

The court is where the lawsuit is pending, overseeing the legal proceedings.

Importance 10.0 Sentiment 0.0

Relationships

ADMA Biologics related ↔ United States — United States District Court for the District of New Jersey

Kahn Swick & Foti related ↔ Charles Foti

Kahn Swick & Foti related ↔ Lewis Kahn

Charles Foti law partner ↔ Lewis Kahn Charles Foti serves as a partner under Managing Partner Lewis Kahn at the securities litigation firm Kahn Swick & Foti.

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard